INTRODUCTION
Rectal cancer is a common disease in the United States, with an estimated 40,000 new cases expected to have been diagnosed in 2015, 1 and a worrisome increase in incidence rates in the younger population. 2 The management of rectal cancer has become more complex, with a greater chance of variation by patient-associated, physician-associated, and treatment facility-associated factors. 3, 4 Trimodality therapy, incorporating total mesorectal excision (TME), pelvic radiotherapy (RT), and systemic chemotherapy, is an established treatment paradigm for patients with American Joint Committee on Cancer stage II and III rectal adenocarcinoma, based on several randomized clinical trials. 5, 6 A previous analysis of the National Cancer Data Base (NCDB) regarding the patterns of care in the United States 7 encompassed the period between 1985 and 1995 and revealed a dramatic increase in the receipt of trimodality therapy: from 9.5% between 1985 and 1986 to 31% between 1989 and 1990, and again to 46% between 1994 and 1995. This trend was based, in part, on a National Cancer Institute consensus statement that was published in 1990. 8 In addition, the publication of the phase 3 randomized trial of the German Rectal Cancer Study Group in 2004 9 established neoadjuvant chemoradiotherapy (NACRT) followed by TME as a standard of care in the United States, based on improvements in local control, decreased toxicity, and a possibly increased rate of sphincter preservation, in comparison with TME followed by adjuvant chemoradiotherapy (CRT). In the current study, we examined contemporary patterns of and factors associated with the receipt of NACRT in the United States.
MATERIALS AND METHODS

Study Population
The NCDB, which is jointly sponsored by the American College of Surgeons Commission on Cancer and the American Cancer Society, is a hospital-based registry that serves as a comprehensive clinical surveillance resource that derives its data from approximately 1500 Commission on Cancer-accredited programs in the United States. As such, the NCDB captures approximately 70% of incident cancers in the United States each year, making it one of the most powerful and generalizable cancer databases in the world. 10 Ongoing validation of the accuracy and quality of the NCDB data is performed through internal monitoring, site surveys, and data quality reviews.
11 Data coding methods have been described previously. 12 We extracted data regarding patients aged >18 years who were diagnosed with a single primary or first primary American Joint Committee on Cancer stage II to III rectal adenocarcinoma and received all or part of their treatment at an accredited NCDB facility between January 1, 2004 and December 31, 2012. Rectal carcinoma cases include cancers topographically coded as C20.9, according to the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). 13 Treatment of all cases was analyzed using the clinical stage of disease (pathologic stage was used if the clinical stage was missing) at the time of diagnosis. Management strategies for rectal carcinoma include surgery, chemotherapy, RT, and combinations of these modalities. Disease histology was limited to rectal adenocarcinomas (ICD-0-3 histology codes 8140, 8210, 8260-63, 8470, 8480, and 8481), including adenocarcinoma, not otherwise specified; adenocarcinoma in adenomatous polyps; papillary adenocarcinoma, not otherwise specified; villous adenocarcinoma; adenocarcinoma in tubulovillous adenoma; mucinous adenocarcinoma; and mucinproducing adenocarcinoma. Tumors recorded as other carcinomas or with unspecified histology codes were excluded from the current analysis. Information retrieved included type of surgery, patient age, patient sex, patient race (categorized as non-Hispanic [NH] white, NH black, Hispanic, or other/missing data/unknown), patient insurance (private, Medicaid, Medicare, uninsured, or other/ missing data), facility type, facility volume (tertiles of facility case volume were ranked into low, medium, and high case volumes by counting the number of cases treated at the facility), educational attainment (defined as the percentage of residents per ZIP code without a high school diploma), date of diagnosis, date of surgery, date chemotherapy was initiated, date RT was initiated, receipt of chemotherapy, receipt of RT, number of RT fractions, lymph node status, tumor grade, tumor size, and comorbidity score. We defined adjuvant therapy as when treatment was administered within 6 months after surgical resection, and also defined neoadjuvant therapy as when treatment was administered within 6 months before surgical resection. Receipt of NACRT and adjuvant CRT were categorized based on receipt of chemotherapy and RT within the specified time frame. For the trend analysis, all patients were grouped according to predetermined time 
Statistical Analysis
We used SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC) to perform the statistical analysis. We performed descriptive analysis to demonstrate patterns of NACRT using chi-square tests to test significance for categorical variables and the Cochran-Armitage test for trend to determine trends over time in the use of NACRT for 3 time periods (2004-2006, 2007-2009, and 2010-2012) . Variables likely to be associated with the receipt of preoperative treatment and the type of preoperative treatment were included in the multivariable logistic regression model. All-cause, unadjusted, 5-year survival rates were calculated using the Kaplan-Meier method. Follow-up time for calculating survival rates was from the date of diagnosis until the date the study ended (December 31, 2012), last contact date, or death (whichever occurred first). Cox proportional hazards models were used to estimate the 5-year risk of all-cause mortality and to identify independent predictors of survival. The proportional hazards assumption test did not show violations for variables included in the model. Statistical significance was considered when the 2-sided P value was < .05.
RESULTS
Patient Demographics
We identified 68,182 patients in the NCDB who received a diagnosis of stage II or III rectal cancer between 2004 and 2012. No significant differences were evident with regard to the sociodemographic and clinical characteristics of the patients (age, ethnicity, comorbidity score, insurance, Original Article income, or education) among the 3 diagnosis periods ( Table 1) . The majority of patients (>70%) diagnosed with locally advanced rectal cancer were aged 50 to 79 years, and the vast majority had excellent performance status with a comorbidity score (Charlson/Deyo) of 0.
Tumor Characteristics
Overall, the quality of documentation of tumor characteristics was good, with no apparent changes between 2004 and 2012. Approximately 10% of patients were missing information regarding tumor grade and 20% were missing information regarding tumor size. No significant changes in tumor characteristics were observed among the 3 diagnosis-year cohorts (Table 1) , and there was a nearly equal split between patients with stage II and stage III disease at the time of diagnosis.
Patterns of Treatment
The majority of patients were treated at comprehensive community cancer programs, and the percentage of patients treated at facilities with low case volumes substantially decreased from 12. 6 .7% between 2010 and 2012, whereas receipt of NACRT increased from 42.9% to 50.6% and then to 55% over the 3 time periods (P for trend < .0001) (Fig. 1 ). Less than 1% of patients received short-course RT, defined as 5 sessions. The majority of patients received standard fractionation RT (between 25 and 33 fractions).
Factors Associated With Receipt of NACRT
Patients who were diagnosed with more advanced disease (larger tumors and involved pelvic lymph nodes) were more likely to undergo either surgery alone or surgery followed by adjuvant CRT and less likely to receive NACRT. Patients treated at facilities that did not have a high case volume (as defined earlier) were less likely to receive NACRT. Several social factors were found to be associated with a lower likelihood of receiving NACRT: nonwhite ethnicity, lack of private medical insurance, and residing in a neighborhood with a low educational background (Table 3) .
Survival Outcomes
A total of 28,550 patients diagnosed with stage II or III rectal cancer between 2004 and 2007 were analyzed for 5-year survival outcomes. The 5-year unadjusted overall survival (OS) rate was 72.4%, 70.9%, 44.9%, and 48.8%, respectively, among patients who received NACRT, adjuvant CRT, surgery alone, and definitive CRT (Fig. 2) . When compared with patients who received NACRT, the adjusted hazard ratio for risk of death at 5 years was 1.66 (95% confidence interval, 1.56-1.77) for surgery alone and 1.48 (95% confidence interval, 1.37-1.59) for definitive CRT (Table 4 ). Black race, older age at the time of diagnosis, high tumor grade, increased tumor size, involved lymph nodes, higher comorbidity score, treatment facilities that did not have a high case volume, nonprivate insurance, and lower median income were found to be associated with a higher risk of death at 5 years after treatment for stage II or III rectal cancer.
DISCUSSION
The treatment paradigm for locally advanced rectal cancer has been shifting continuously over the past 30 years to incorporate 3 treatment modalities (surgery, chemotherapy, and RT) to achieve best treatment outcomes. An earlier report concerning patterns of care for rectal cancer in the United States based on an analysis of NCDB data revealed the receipt of trimodality therapy (with no information regarding the sequencing of these modalities) in 9.5% of patients with stage II or III rectal cancer between 1985 and 1986, which increased to 31% between 1989 and 1990 and further increased to 46% between 1994 and 1995 (calculated from Table 4 in Jessup et al  7 ) . This trend could be attributed in part to the publication of the National Cancer Institute consensus statement in 1990. 8 We extended this analysis through 2012 and demonstrated that the percentage of US patients receiving trimodality therapy (either NACRT followed by surgery or surgery followed by adjuvant CRT) has been steady at approximately 60% over the past decade. We also demonstrated that, in keeping with several randomized clinical trials, the use of trimodality therapy is associated with the best OS rate of >70%.
A randomized trial of NACRT versus adjuvant CRT, published in 2004, established NACRT as a standard of care in Europe and North America. Although there was no survival difference noted, NACRT led to improved local control, decreased severe acute and long-term treatment-related Original Article toxicities, and possibly improved the rate of sphincter preservation, in comparison with adjuvant CRT. 9 Over the past decade, since the publication of the randomized trial by the German Rectal Cancer Study Group, 9 we have observed an increase in the rate of adoption of NACRT in the management of patients with locally advanced rectal cancer in the United States, with the parallel decrease in the use of adjuvant CRT. Unfortunately, with only 55% of US patients receiving the standard of treatment in recent years, one must address the gap between the guidelines and the variable penetrance into routine clinical practice. The results of the current study indicate that facilities with low or medium case volumes are less likely to offer patients the standard treatment, and that socioeconomic factors such as not being of NH white race/ ethnicity, a lack of private insurance, and residence in a neighborhood with a lower educational background are independent factors associated with a lower probability of receiving the standard national guidelines-supported therapies.
The standard trimodality therapy in the United States involves a fractionated RT treatment course over 5 weeks with concurrent chemotherapy, followed by surgery. This treatment paradigm is costly for the health care system to support. Conversely, short-course RT of 25 Gy delivered in 5 fractions followed by immediate surgery, without concurrent chemotherapy, has a long history of evaluation in Europe. Recently, 2 randomized trials compared long-course CRT with short-course RT. A Polish randomized trial demonstrated no benefit from the long- course CRT in terms of sphincter preservation, local control, or survival, while the local control trend actually favored short-course RT. 14 A more recent Trans-Tasman Radiation Oncology Group trial compared short-course RT with long-course CRT in patients with T3 rectal cancer defined on ultrasound or magnetic resonance imaging, with all patients receiving chemotherapy with 5-fluorouracil. 15 This trial did not demonstrate any difference in local control or OS. The results of the current study demonstrate that <1% of US patients over the past decade received short-course RT, defined as 5 fractions, usually given within a span of 1 week. This is in stark contrast to Sweden, where approximately 80% of patients were reported to receive short-course RT and only 20% of patients received long-course CRT, based on a recent analysis of the Swedish National Patient Register. 16 Because access to health care, such as the availability of transportation, and treatment costs prevent US patients from receiving the standard trimodality therapy, 17, 18 short-course neoadjuvant RT should be strongly considered as a reasonable and evidence-based alternative. In general, as the debate over the cost-effectiveness of oncology care in the United States continues, many health care systems are searching for ways to minimize expensive treatments in areas in which clinical evidence exists to support the alternative, less costly treatment approaches. The NCDB is a comprehensive national oncologic database with detailed information available regarding sociodemographic, tumor, and treatment characteristics. 19 Several comparison studies have documented the validity of NCDB-based analysis. 20, 21 However, the current study has several limitations. Despite the fact that the clinical and demographic characteristics of patients in the NCDB have been shown to be similar to those of patients in the population-based Surveillance, Epidemiology, and End Results database, 22 the NCDB remains a hospital-based cancer registries database and the results may not be generalizable to the US population. There could be underreporting of the receipt of chemotherapy and RT because these therapies could be administered in the outpatient setting. The NCDB does not collect information regarding provider/ patient preferences and individual socioeconomic factors, which could influence receipt of treatment. Finally, an unadjusted all-cause mortality was used for survival outcomes because the NCDB does not collect cancer-specific mortality, which may not be reflective of treatment effectiveness but rather dependent on patient selection.
Conclusions
In a large national database, the results of the current study demonstrated that the use of NACRT before surgery in US patients diagnosed with locally advanced rectal cancer has substantially increased over the past decade. However, only approximately one-half of these patients currently receive the standard therapy as recommended by national guidelines, which in part could be explained by socioeconomic barriers. Trimodality therapy is associated with the best outcomes for these patients, and surgery alone or definitive CRT should only be reserved for patients who are unable to tolerate trimodality therapy, or for carefully selected patients taking part in clinical trials.
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